FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Quality, Data Issues at Mylan Facility in India

[ Price : $8.95]

FDA warns a Viatris Mylan drug manufacturing facility in Pradesh, India, about CGMP violations involving quality and data issues.

Boxed Warning for Veozah Liver Injury

[ Price : $8.95]

FDA adds a liver injury Boxed Warning to labeling for Astellas menopause hot flash drug Veozah.

Lexicon Dropping Zynquista After CRL

[ Price : $8.95]

Lexicon stops development of its diabetes drug Zynquista that received an FDA complete response letter.

Sombra Cosmetics CGMP Violations

[ Price : $8.95]

FDA warns Albuquerque, NM-based Sombra Cosmetics about CGMP violations in the manufacturing of finished drugs.

FDA OKs Mesoblasts Ryoncil Cell Therapy

[ Price : $8.95]

FDA approves Mesoblasts Ryoncil to treat some graft-versus-host disease pediatric patients.

ICH M15 Model-Informed Drug Development Principles

[ Price : $8.95]

FDA publishes an International Council for Harmonization draft M15 guidance on model-informed drug development principles.

AMT Designation Program Guidance

[ Price : $8.95]

FDA publishes a guidance with recommendations for participating in the agencys Advanced Manufacturing Technologies Designation Pro...

ICH E11A Pediatric Extrapolation Guidance

[ Price : $8.95]

FDA publishes the International Council on Harmonization E11A Pediatric Extrapolation guidance.

ICH Clinical Practice Guide Annex

[ Price : $8.95]

FDA publishes Annex 2 of the International Council on Harmonization Good Clinical Practice guidance.

Brands International Limits, Delays Inspection: FDA

[ Price : $8.95]

FDA warns a Canadian Brands International facility about limiting and delaying an inspection that also identified CGMP violations.